Comparative Pharmacology
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus LUMI SPORYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus LUMI SPORYN.
ELASE-CHLOROMYCETIN vs LUMI-SPORYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
Topical application: Apply thin layer to affected area 2-3 times daily.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
None Documented
None Documented
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Renal 70-80% unchanged, biliary/fecal 20-30%
Category C
Category C
Topical Antibiotic and Debriding Agent
Topical Antibiotic